How do first‑generation antihistamines compare with second‑generation antihistamines regarding risks, efficacy, and current treatment guidelines?

Second-Generation Antihistamines Are Strongly Preferred Over First-Generation Antihistamines

Second-generation antihistamines should be used instead of first-generation antihistamines for treating allergic rhinitis and urticaria due to their superior safety profile, with first-generation agents posing significant risks to morbidity and quality of life through sedation, performance impairment, and anticholinergic effects that patients often don't recognize. 1

Current Treatment Standard

The 2008 Joint Task Force guidelines establish that second-generation antihistamines are generally preferred over first-generation antihistamines for allergic rhinitis treatment 1. This recommendation is based on critical safety differences rather than efficacy differences, as both generations have similar effectiveness for symptom control 1.

Critical Safety Risks of First-Generation Antihistamines

Performance Impairment and Accidents

First-generation antihistamines (diphenhydramine, hydroxyzine, clemastine) cause dangerous impairment that patients frequently don't perceive:

• Drivers taking first-generation antihistamines are 1.5 times more likely to cause fatal automobile accidents 1
• Performance impairment exists without subjective awareness of drowsiness 1
• Workers experience impaired productivity and higher occupational accident rates 1
• Impaired learning and school performance in children 1
• The combination with alcohol or cellular phone use dramatically worsens impairment 1

Anticholinergic Effects

First-generation agents cause problematic anticholinergic effects including 1:

• Dry mouth and eyes
• Constipation
• Urinary retention
• Increased risk of narrow-angle glaucoma
• Cognitive impairment, particularly in elderly patients

High-Risk Populations

Older adults require extra caution with first-generation antihistamines due to 1:

• Increased sensitivity to psychomotor impairment
• Higher risk of falls leading to fractures and subdural hematomas
• Greater susceptibility to anticholinergic effects
• Comorbid conditions (increased intraocular pressure, benign prostatic hypertrophy, preexisting cognitive impairment)

Why Second-Generation Antihistamines Are Superior

Safety Profile

Second-generation antihistamines (fexofenadine, loratadine, desloratadine, cetirizine, levocetirizine) have 1:

• Minimal or no blood-brain barrier penetration 2, 3, 4
• High selectivity for peripheral H1-receptors 2, 5
• Significantly reduced sedation and performance impairment 1
• Minimal anticholinergic effects 1

Important Distinctions Within Second-Generation Agents

Not all second-generation antihistamines are equal regarding sedation 1:

• Non-sedating at recommended doses: Fexofenadine, loratadine, desloratadine 1
• May cause mild sedation at recommended doses: Cetirizine (13.7% vs 6.3% placebo) and intranasal azelastine (11.5% somnolence) 1

Efficacy

Second-generation antihistamines demonstrate 1:

• Equal or superior effectiveness compared to first-generation agents 5, 3
• Rapid onset of action (appropriate for as-needed use) 1
• Effective for seasonal and perennial allergic rhinitis 1
• Less effective than intranasal corticosteroids but appropriate for mild-moderate symptoms 1

Common Pitfalls to Avoid

The AM/PM Dosing Strategy Is Not Recommended

Do not use a cost-saving strategy of second-generation antihistamine in the morning with first-generation at bedtime 1. This approach fails because:

• First-generation antihistamines and their metabolites have prolonged half-lives
• End-organ effects persist longer than plasma levels
• Significant daytime drowsiness and performance impairment occur the next morning
• Patients remain unaware of their impairment 1

Bedtime Dosing Doesn't Eliminate Risk

Even when first-generation antihistamines are dosed only at bedtime, they cause significant next-day drowsiness, decreased alertness, and performance impairment 1.

When First-Generation Antihistamines May Be Considered

The guidelines identify only narrow circumstances where first-generation agents might be appropriate 1:

• When soporific effect is specifically desired at bedtime (with caveat about morning impairment)
• When anticholinergic properties are advantageous (e.g., persistent rhinorrhea despite second-generation antihistamine plus intranasal corticosteroid)
• However, even in these cases, a topical anticholinergic agent (ipratropium) is preferred over systemic anticholinergic effects 1

Before prescribing first-generation antihistamines, physicians must ensure patients understand the potential dangers and availability of safer alternatives 1.

Updated Treatment Approach (2020 ARIA Guidelines)

The next-generation ARIA guidelines using real-world evidence from mobile health technology confirm 6:

• Intranasal corticosteroids remain first-line for moderate-to-severe rhinitis
• Oral H1-antihistamines are less potent than intranasal corticosteroids, but many patients prefer oral drugs
• Most patients self-medicate and use on-demand treatment
• Patients reporting second-generation antihistamine monotherapy have better control than those using first-generation agents

Specific Agent Selection

Among second-generation antihistamines, no single agent achieves conclusively superior overall response rates 1. Selection should prioritize:

1. For zero sedation risk: Fexofenadine, loratadine, or desloratadine 1
2. For chronic urticaria: Recent evidence suggests olopatadine and ebastine show promising efficacy, with fexofenadine having the lowest adverse reaction rate 7, 8
3. For patients requiring minimal CNS effects: Avoid cetirizine and intranasal azelastine if sedation is a concern 1

Regulatory and Public Health Perspective

First-generation antihistamines obtained over-the-counter represent a significant public health concern 9:

• The general public doesn't recognize their potential dangers
• They're implicated in civil aviation, motor vehicle, and boating accidents
• Deaths from accidental or intentional overdosing in infants and children
• Suicide in teenagers and adults
• Some exhibit cardiotoxicity in overdose

The recommendation is that first-generation antihistamines should no longer be available over-the-counter now that safer second-generation alternatives are widely available at competitive prices 9.